ライフサイエンスコーパス: beta-emitter

1 troscopic data (the former isotope is a weak beta emitter).

2 radiated patients, including both gamma and beta emitters.

3 tector and has been optimized for low-energy beta emitters.

4 ss damage to surrounding normal tissues than beta-emitters.

5 dionuclide S values for intermediate-to-high beta-emitters.

6 itters (148)Gd, (154)Dy, and (146)Sm and the beta-emitters (129)I and (36)Cl from proton-irradiated t

7 chosen for the separation of the long-lived beta-emitters (129)I, (36)Cl and the alpha-emitters (154

8 as also compared in vivo with the low-energy beta-emitter (131)I-tositumomab and the high-energy beta

9 emitters (18)F, (64)Cu, (89)Zr, and (124)I; beta-emitter (131)I; and alpha-particle emitter (225)Ac

10 onoclonal antibodies (mAbs) labeled with the beta-emitters (131)I and (90)Y and the alpha-emitter (21

11 When labeled with the beta-emitters (131)I and (90)Y, HuM195 can eliminate lar

12 approximately 4%-25% for intermediate-energy beta-emitters ((153)Sm, (186)Re, and (89)Sr), and by app

13 ic efficacy of the alpha-emitter (149)Tb and beta(-)-emitter (161)Tb.

14 ecause of different physical properties, the beta-emitters (177)Lu and (90)Y offer specific radiologi

15 Treatment with the beta-emitter [(177)Lu]Lu-PSMA-617, approved in 2022, has

16 Results: In a dose-response study with the beta-emitter 177Lu-DOTA-daratumumab, the lowest tested d

17 labeled with 1.5 mCi (1 Ci = 37 GBq) of the beta-emitter 188-Rhenium (188Re) and manifested inhibiti

18 Results using the beta-emitters (188)Re, (177)Lu, and (90)Y and the alpha-

19 , (90)Sr, (103)Ru, (106)Ru, plutonium), pure beta-emitters ((3)H, (14)C, (35)S), gaseous radionuclide

20 and by approximately 11%-30% for high-energy beta-emitters ((32)P, (188)Re, and (90)Y).

21 old therapeutic advantage over the energetic beta emitter 32P.

22 Vascular brachytherapy using pure beta-emitter 32P delivered into a centreing catheter via

23 sites by approximately 4%-23% for low-energy beta-emitters ((33)P, (169)Er, and (177)Lu), by approxim

24 true theranostic twins using (61)Cu and the beta(-)-emitter (67)Cu is also feasible.

25 -dichloride, and the second will discuss the beta emitters (89)Sr and (153)Sm-EDTMP.

26 ed to examine the efficacy and safety of the beta-emitter 90-yttrium for the prevention of recurrent

27 ng component of the decay scheme of the pure beta-emitter (90)Y has traditionally been ignored in int

28 With the beta-emitter (90)Y, all of the 10 lymphoma-xenografted m

29 itter (131)I-tositumomab and the high-energy beta-emitter (90)Y-rituximab.

30 The use of the beta-emitter 90Sr/Y significantly reduced treatment time

31 beta emitters are limited by lower energies and nonspeci

32 chemicals tagged with low-energy electron or beta emitters are the radiopharmaceuticals of choice for

33 t radioactivity concentrations of alpha- and beta-emitters bound to mAbs were compared.

34 e and others have shown that such low-energy beta-emitters can cause cell cycle arrest and apoptosis

35 considered alpha- and low- to medium-energy beta-emitters considerably affected the absorbed dose es

36 Intravascular irradiation with beta-emitters has been proposed for inhibition of resten

37 n the clinical setting, the effectiveness of beta-emitters has not been studied in a broad spectrum o

38 radiation therapy, utilizing both gamma and beta-emitters, has been shown to reduce the rate of ISR.

39 the advantages and drawbacks of varying the beta-emitter in PSMA-targeting radioligand therapy.

40 We demonstrate that the (177)Lu (beta-emitter) in this fullerene cage is not significantl

41 in nuclear medicine was based on the use of beta(-) emitter-labeled peptides as receptor-specific th

42 TheraSphere consists of yttrium-90 (a pure beta emitter) microspheres, which are injected into the

43 Its daughter (99)Tc is a beta emitter of great concern because of its long half-l

44 Because 90Y is a beta emitter, quantitative information from imaging is s

45 For a pure beta -emitter such as (90)Y, marrow dose is usually dete

46 nd their statistical distribution for a pure beta emitter such as 90Y take approximately 1 min on a 3

47 e sparing the bone marrow than are energetic beta emitters such as 32p and 89Sr.

48 e that metabolically incorporated low-energy beta-emitters such as [(35)S]methionine and (3)H-thymidi

49 that metabolic incorporation of a low energy beta-emitter, such as 35S-methionine, can globally influ

50 Because (90)Y is a pure beta-emitter, the requisite safety precautions are not o

51 world clinical outcomes of sequential alpha-/beta-emitter therapy for metastatic castration-resistant

52 hecking for a radiotracer that can deliver a beta(-) emitter to the tumor is a fundamental step in th

53 ue, a suitable radiotracer able to deliver a beta- emitter to the tumor has to be identified.

54 tudy require a reevaluation using low-energy beta-emitters to follow not only experimental protocols

55 For beta-emitters, tumors will receive almost entirely nonsp

56 ted the feasibility of sequential alpha- and beta-emitter use in patients with bone-predominant metas

57 r ZCE025) in combination with long half-life beta(-)-emitters was optimal, yet inadequate as the sole

58 (99)Tc is an artificial beta emitter widely used in nuclear medicine for diagnos

59 ear absorbed doses from (177)Lu and (161)Tb (beta(-)-emitter with additional conversion and Auger ele

60 n microspheres (SIR Spheres)--containing the beta-emitter, yttrium-90--into the arterial supply of th